or Try an Advanced Search...

    Technical Analysis for IMAB - I-Mab

    Grade Last Price % Change Price Change
    F 1.62 -2.99% -0.05
    IMAB closed down 2.99 percent on Monday, July 1, 2024, on 49 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical IMAB trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 200 DMA Bearish -2.99%
    Down 3 Days in a Row Weakness -2.99%
    Oversold Stochastic Weakness -2.99%
    200 DMA Support Bullish -4.14%
    Stochastic Reached Oversold Weakness -4.14%
    Outside Day Range Expansion -4.14%
    Older End-of-Day Signals for IMAB ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 7 hours ago
    Fell Below Previous Day's Low about 7 hours ago
    Down 2 % about 8 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    Down 1% about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    IMAB Chart by TradingView
    Basic chart:

    Profile

    I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Disease Pharmacy Medication Autoimmune Disorders Immune Disorders

    Is IMAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 7 While private equity firms own 21% of I-Mab (NASDAQ:IMAB), retail investors are its largest shareholders with 59% ownership
    Jun 6 I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
    Jun 6 I-Mab and BMS assess givastomig for gastric and oesophageal cancer
    Jun 5 I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
    May 23 I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
    May 22 I-Mab to Participate at the Jefferies Global Healthcare Conference
    May 7 (IMAB) - Analyzing I-MAB's Short Interest
    May 2 Q1 2024 Summit Therapeutics Inc Earnings Call
    Apr 30 I-MAB Filed 2023 Annual Report on Form 20-F
    Apr 5 I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
    See more IMAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.17
    52 Week Low 1.16
    Average Volume 210,982
    200-Day Moving Average 1.68
    50-Day Moving Average 1.78
    20-Day Moving Average 1.77
    10-Day Moving Average 1.71
    Average True Range 0.08
    RSI (14) 33.33
    ADX 18.05
    +DI 12.77
    -DI 22.12
    Chandelier Exit (Long, 3 ATRs) 1.75
    Chandelier Exit (Short, 3 ATRs) 1.76
    Upper Bollinger Bands 1.97
    Lower Bollinger Band 1.58
    Percent B (%b) 0.1
    BandWidth 21.80
    MACD Line -0.03
    MACD Signal Line -0.02
    MACD Histogram -0.0177
    Fundamentals Value
    Market Cap 133.85 Million
    Num Shares 82.6 Million
    EPS -3.78
    Price-to-Earnings (P/E) Ratio -0.43
    Price-to-Sales 2.55
    Price-to-Book 0.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.74
    Resistance 3 (R3) 1.74 1.71 1.72
    Resistance 2 (R2) 1.71 1.68 1.71 1.71
    Resistance 1 (R1) 1.66 1.66 1.65 1.66 1.71
    Pivot Point 1.63 1.63 1.62 1.63 1.63
    Support 1 (S1) 1.58 1.60 1.57 1.58 1.53
    Support 2 (S2) 1.55 1.58 1.55 1.53
    Support 3 (S3) 1.50 1.55 1.52
    Support 4 (S4) 1.50